Henry Schein Q3 Earnings, Sales Climb; Lifts 2026 Adj. Income Outlook

Henry Schein (HSIC) reported Q3 earnings, noting pressure in discretionary procedures but strong growth in global dental and specialty products. U.S. dental equipment sales rose 1.6%, while global distribution and value-added services increased 3.7%. The company raised its non-GAAP EPS outlook to $5.50-$5.56. Management expects 2026 sales growth of 4.5%-5.5% and high-single-digit adjusted EBITDA growth.

Henry Schein reported Q3 2026 US dental merchandise growth of 8.6%, driven by volume. The company targets $200M in operating income improvements by 2026, with $125M expected by year-end. Non-GAAP EPS guidance raised to $5.50–$5.56. Management expects double-digit EPS growth in 2027, supported by value creation initiatives and portfolio shifts. Q3 included a $0.19 per share tariff refund benefit and $22M in restructuring expenses. Emmanuel Capre will succeed Ronald South as CFO in November 2026.

Henry Schein (HSIC) reported Q3 2026 earnings of $1.56 per share, beating estimates, but revenue of $3.47B missed expectations. Shares fell 5.33% premarket. The company raised full-year EPS guidance to $5.50-$5.56 and highlighted growth in U.S. dental merchandise and margin expansion.

Henry Schein (HSIC) reported Q3 adjusted EPS of $1.56, beating estimates by $0.20, while revenue rose 4.0% to $3.47B, missing slightly. The company raised its full-year EPS guidance to $5.50–$5.56 and adjusted EBITDA growth outlook to high-single digits, driven by strong dental sales and improved profitability.

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS STRONG 2026 THIRD QUARTER AND RAISES FY2026 GUIDANCE ● Q3 2026 GAAP diluted EPS of $1.06, up 26.2% versus prior year; Q3 2026 non-GAAP diluted EPS of $1.56, up 13.0% versus prior year ● 4.0% total sales growth, driven by 8.6% U.

Henry Schein reported Q3 2026 revenue of $3.47B, matching estimates, and adjusted EPS of $1.56, beating estimates by 14.9%. Adjusted EBITDA was $321M, also a beat. Management raised full-year adjusted EPS guidance to $5.53. Organic revenue grew 3.1% year-on-year, missing expectations.